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Particulateadjuvantshaveshown increasingpromiseaseffective, safe, anddurableagents
for the stimulation of immunity, or alternatively, the suppression of autoimmunity. Here
we examined the potential of the adjuvant carbonyl iron (CI) for themodulation of organ-
specific autoimmune diseasetype 1 diabetes (T1D). T1D was induced by multiple low
doses of streptozotocin (MLDS) that initiates beta cell death and triggers immune cell
infiltration into thepancreatic islets. The resultsof this study indicate that the single in vivo
application of CI to MLDS-treated DA rats, CBA/H mice, or C57BL/6 mice successfully
counteracted the development of insulitis and hyperglycemia. The protective action was
obtained either when CI was applied 7 days before, simultaneously with the first dose of
streptozotocin, or 1 day after MLDS treatment. Ex vivo cell analysis of C57BL/6 mice
showed that CI treatment reduced the proportion of proinflammatory F4/80+CD40+M1
macrophages and activated T lymphocytes in the spleen.Moreover, the treatment down-
regulated the number of inflammatory CD4+IFN-γ+ cells in pancreatic lymph nodes,
Peyer's patches, and pancreas-infiltrating mononuclear cells, while simultaneously
potentiating proportion of CD4+IL17+ cells. The regulatory arm of the immune system
represented by CD3+NK1.1+ (NKT) and CD4+CD25+FoxP3+ regulatory T cells was
potentiated afterCI treatment. In vitro analysis showed thatCI down-regulatedCD40and
CD80expressionondendritic cells thusprobably interferingwith their antigen-presenting
ability. In conclusion, particulateadjuvantCI seems to suppress theactivationof the innate
immune response, which further affects the adaptive immune response directed toward
pancreatic beta cells.
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1 | INTRODUCTION
Type 1diabetes (T1D) is a chronic autoimmune disease characterized
by progressive destruction of insulin-producing pancreatic beta cells
and hyperglycemia. A variety of immune cells including dendritic cells,
macrophages, natural killer (NK) cells, T and B cells have been shown to
participate in diabetes pathogenesis (Greeley et al., 2002). Macro-
phages and dendritic cells (DC) are among the earliest invading cells in
the pancreas and they attract T and B lymphocytes that continue beta
cell destruction (Nikolic, Geutskens, van Rooijen, Drexhage, & Leenen,
2005). In the setting of overactive innate immune responses, a therapy
that could retune innate immune responses might have beneficial
downstream effects on adaptive immunity as well.
Any substance that can enhance specific immune response to co-
inoculated antigen is called an adjuvant (Israeli, Agmon-Levin, Blank, &
Shoenfeld, 2009). So far, several 100 natural and synthetic compounds
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havebeen identified tohaveadjuvant activity (Petrovsky&Aguilar, 2004).
The use of particulate adjuvants offers an interesting opportunity to
enhance, or alternatively suppress the immune responses (Langridge,
Dénes, & Fodor, 2010). Severalmechanismsof adjuvant-induced immune
response have been proposed: themode of antigen delivery, activation of
innate immunity via pattern recognition receptors such as Toll-like
(Madan-Lala, Pradhan,&Roy, 2017) orNOD-like receptors (Girardinet al.,
2003), increasing the antigen uptake by antigen-presenting cells (APC),
altering the cytokine expression by secondary stimulation of APC
(Perriconeet al., 2013). As strong activators of immune response,
adjuvants' use has been mandatory in the induction protocols of many
experimental models of autoimmune diseases, such as experimental
autoimmune encephalomyelitis (EAE), neuritis, uveitis, thyroiditis, and
orchitis (reviewed in Billau &Matthys, 2001; Stratmann, 2015). However,
opposing effects were also observed as exposure to complete Freund's
adjuvant (CFA)was shown to suppress the severity of EAE in rats andT1D
development in BB rats and NOD mice (Kies & Alvord, 1958; Lee, Qin,
Priatel, & Tan, 2008; Sadelain, Qin, Lauzon, & Singh, 1990; Sadelain, Qin,
Sumoski, et al., 1990). It has been reported that liveMycobacterium avium
or bacillus Calmette-Guerin (BCG) can also suppress T1D development in
NODmice (Martins&Aguas, 1999; Yagi et al., 1991). Furthermore, recent
clinical studies have revealed that BCG vaccination exerted anti-
inflammatory effects in diseases such as multiple sclerosis or T1D
(Lagranderie&Guyonvarc'h, 2014; Ristori et al., 2014). Although all of the
mentioned adjuvants suppress autoimmune response, their mechanisms
of action may vary from inhibition of dendritic cell maturation and
autoreactiveTcell generation, selectiveeliminationofautoreactiveTcells,
to stimulation of Th2 cell, secretion of immunosuppressive cytokines, and
activation of T regulatory cells (Treg).
Carbonyl iron (CI) is a form of metallic iron characterized by
spherical particles. It possesses adjuvant properties as the immuniza-
tion of rats with CI and spinal cord homogenate (in the absence of
bacterial components) promotes the infiltration of granulocytes and
NK cells into the CNS and activation of microglia that leads to EAE
development (Miljkovic, Momcilovic, Stanojevic, Rasic, & Mostarica-
Stojkovic, 2011; Staykova, Liñares, Fordham, Paridaen, & Willenborg,
2008). Interestingly, adjuvant activity was not found in other forms of
metallic iron, or other metallic iron suspensions such as iron oxide or
iron-dextran (Levine & Sowinski, 1970). However, the potential role of
CI as a modulator of organ-specific autoimmunity has not been
investigated so far. To define the role of CI in T1D pathogenesis, we
have evaluated the impact of this agent in the animal model of T1D,
where the diseasewas induced bymultiple lowdoses of streptozotocin
(MLDS) and determined the possible mechanism of CI action.
2 | MATERIALS AND METHODS
2.1 | Materials and reagents
All chemicals, unless otherwise noted, were obtained from Sigma
Aldrich (St. Louis, MO), and cell culture reagents were from Life
Technologies (Grand Island, NY). CI (SigmaAldrich, Steinheim,
Germany) was prepared as an aqueous suspension.
2.2 | Animals and treatment groups
Male C57BL/6 and CBA/H mice at 810 weeks of age and male Dark
Agouti (DA) rats (68 week of age) were bred and kept in the animal
facility of the Institute for Biological Research Sinisa Stankovic,
University of Belgrade. Their usage and all experimental procedures
were approved by the Ethic Committee at the Institute for Biological
Research Sinisa Stankovic (App. No 2-27/10-01-189) in accordance
with the Directive 2010/63/EU. Rodents were kept in conventional
conditions with an underlying 12-hr day/night rhythm and free access
to standard rodent chow and water. Animals were randomly assigned
to control or CI groups. All groups were comprised of 710 animals.
2.3 | T1D induction and treatment protocols
Immunoinflammatory T1D was induced in male C57BL/6 and CBA/H
mice and DA rats with MLDS (40mg/kg bw in C57BL/6 and CBA/H,
20mg/kg bw in DA rats), i.p, for 5 consecutive days as described
previously (Stosic-Grujicic et al., 2001). Animals were treated with a
single i.p. injection of CI (25mg/kg bw, treatment group) or PBS as a
vehicle (control group). Day 0 was the day of the first streptozotocin
(STZ) injection. CI was administered in early prophylactic (7 days
before first STZ injection), prophylactic (at the sameday as the first STZ
injection), and therapeutic (5 days after the first STZ shot) manner.
Rodents were monitored for the development of hyperglycemia by
weekly measurements of blood glucose levels, using a glucometer
(Sensimac, IMACO GmbH, Lüdersdorf, Germany). Animals were
considered hyperglycaemic if their blood glucose level was higher
than10mmol/l in non-fasted animals. Toxic diabetes was induced in
male C57BL/6 mice with a single i.p. injection of high dose of STZ
(200mg/kg bw). Animals were simultaneously treated intraperitone-
ally with CI (25mg/kg bw). Glycemia levels weremeasured 3 days after
STZ injection.
2.4 | Cell preparation
Ex vivo analysis was performed on MLDS-induced C57BL/6 mice on
day 15 of post-diabetes induction and after prophylactic CI treatment.
Animals were killed by cervical dislocation and peritoneal cells (PC)
were collected by lavage of peritoneal cavity with cold PBS containing
heparin (5 U/ml). Single cell suspensions from spleen, pancreatic lymph
nodes, Peyer's patches, mesenteric lymph nodes, and pancreas-
infiltrating mononuclear cells (PIMC) were obtained as previously
described (Nikolic et al., 2014; Stanisavljević et al., 2017).
The obtained cell pellet was re-suspended in fluorescence-
activated cell sorting buffer (PBS with 1% BSA, pH 7.4) and 1 × 106
cells per sample were used for flow cytometry analysis. Alternatively,
spleen cells (SC) were re-suspended in RPMI-1640 medium (with
25mmol/L HEPES, 2mmol/L L-glutamine) supplementedwith 5% FCS
(PAA Chemicals, Pasching, Austria), penicillin/streptomycin and 5 μM
β-mercaptoethanol and seeded at a density of 5 × 106 cells per ml in
24-well culture plates. After 48 hr supernatants were collected and
stored at −20 °C until their analysis for cytokine production.
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For in vitro generation of dendritic cells (DC), monocytes were
isolated from femur-derived marrow of C57BL/6 mice. Bones
were flushed aseptically with RPMI1640 + 10% FBS and cells were
centrifuged, erythrocytes lysed with RBC lysis buffer (eBioscience,
San Diego, CA) and cells resuspended in RPMI1640 supplemented
with 20%FBS, 4 mML-glutamine and 0.02mMNa-pyruvate. Obtained
cells were cultivated with 20 ng/ml GM-CSF (Peprotech, London, UK)
for 7 days with medium change every second day. After 7 days these
cells can be designated as immature DC. For gaining mature DC, cells
were treated with 100 ng/ml LPS (SigmaAldrich) for 24 hr. For flow
cytometry analysis, 1 × 106 immature DC, mature DC or immature DC
stimulated with 100 ng/ml LPS were seeded in 24-well plates and
treated with 250 μg/ml CI for 24 hr.
CD4+Tcellswereobtained fromsingle cell suspensionsofC57BL/6
lymph nodes (cervical, mesenteric, pancreatic) by magnetic separation.
Briefly, 70 × 106 cells were washed in cold PBS and resuspended in cold
PBS 3% FCS with biotin-labelled rat anti-mouse IgG2bκ CD4
(eBioscience). After 15min incubation on ice, cells were washed and
resuspended in PBS 0.5% BSA 2mM EDTA with streptavidin-labeled
magnetic beads (BD Biosciences, Franklin Lakes, NJ) for 15min on
+4 °C. After that, cells were exposed to magnetic field and excess
solutionwas removed. Remained cellswerewashed and resuspended in
RPMI1640 + 5% FCS. For detection of IFN-γ production, 2 × 106 CD4+
T cells were co-cultivated with 1 × 106mature DC in 24-well plates and
treated with 250 µg/ml CI for 24 hr, stained and analyzed on flow
cytometer. For detection of signaling pathways important for IFN-γ
production, 10 × 106cells isolated from lymph nodes (cervical, mesen-
teric, pancreatic) of C57BL/6 mouse were seeded in 24-well plates,
stimulated with 10 ng/ml recombinant mouse IL-12 (R&D Systems,
Abingdon, UK) and treated with 250 μg/ml CI for 48 hr. After that, cells
were appropriately stained and analyzed on flow cytometer.
2.5 | Histological analysis
To assess the incidence of inflammatory changes and the degree of
islet cell destruction, histologic sections of pancreata (5 µm thick, at
least 200 µm between sections) were stained with Mayer's haema-
toxylin (Bio-Optica) and examined by light microscopy (Zeiss Imager
Z1,AXIO, Oberkochen, Germany). Insulitis scoring was performed by
examining at least 20 islets per pancreas and graded in a blinded
fashion as follows: grade 0, intact islet; grade 1, peri-islet infiltrate;
grade 2, heavy intra-islet infiltrate. Results are expressed as a
percentage of graded islets out of the total number of islets.
2.6 | Measurement of cytokine levels
Cytokine concentration in 48 hr SC culture supernatants was
determined by sandwich ELISA usingMaxiSorp plates (Nunck, Rochild,
Denmark) and anti-mouse paired antibodies according to the
manufacturer's instructions. Samples were analyzed in duplicate for
murine IL-17, IL-4, IL-10, and IFN-γ (eBioscience). Absorbance was
measured by LKB 5060006 microplate reader (LKB Instruments,
Vienna, Austria) at 450 and 570 nm.
2.7 | Assessment of insulin
An ELISA kit (Mercodia, Uppsala, Sweden) was used according to the
manufacturer's instructions to determine insulin concentration in the
sera of non-fasted mice.
2.8 | Measurement of intracellular nitric oxide and
nitrite accumulation
4-Amino-5-methylamino-27-difluoro-fluorescein diacetate (DAF-FM
diacetate; Molecular Probes, Leiden, The Netherlands) was used as an
indicator of intracellular nitric oxide (NO). Briefly, PC cells were
incubated with 2 μM DAF-FM diacetate for 1 hr at 37 °C, washed, and
then incubated for 15min at 37 °C in phenol red- and serum-freeRPMI-
1640 for the completion of de-esterification of intracellular diacetates.
The cells were than washed and PBS was added. Green (FL1)
fluorescence emission was measured with Partec CyFlow Space and
analyzed by FlowMax software (Partec, Görlitz, Germany).
Nitrite accumulation, an indicator of NO release in the superna-
tant, was detected by Griess reaction as described previously
(Stojanovic, Saksida, Nikolic, Nicoletti, & Stosic-Grujicic, 2012).
2.9 | Suppressor assay by PC-LNC co-cultivation
PCwere isolated onday 15 fromMLDS-inducedmice treated or notwith CI.
EachPCsuspensionwasapoolfromthreetofiveanimals.Cells (104cells/well)
were co-cultured with cervical lymph node cells freshly isolated from normal
untreated mice (LNC, 5×105 cells/well), in 96-well flat-bottomed microcul-
ture plates in 0.2ml of standard RPMI-1640 medium in the presence of
1µg/ml concanavalin A (ConA). After 48hr cell culture supernatants were
collected for determination of NO production, while cells were pulsed with
1µCi [3H] thymidine (ICN, Costa Mesa, CA) for another 18hr for
determination of cell proliferation. Incorporated radioactivity in triplicate
cultures was measured in a liquid scintillation counter (Beckman Coulter,
Fullerton, CA). Themagnitude of the proliferative responsewas expressed as
mean counts per minute (cpm) in triplicate co-cultures±SD.
2.10 | Immunofluorescence analysis
The phenotype of SC, PLN, PIMC, and PP, as well as the phenotype of
pooled lymph nodes and bone marrow-derived dendritic cells in in vitro
experiments was assessed by flow cytometry using the anti-mouse
antibodies specific for rat anti-mouse IgG2a F4/80 FITC (eBioscience),
Armenian hamster anti-mouse IgM CD40 APC (eBioscience); goat anti-
mouse IgG CD206-PE (R&D), mouse anti-mouse IgG NK1.1 (BD
Pharmingen, Franklin Lakes, NJ), Armenian hamster anti-mouse IgG
CD3 PE, CD80 PE-Cyanine 5, CD11c PE-Cyanine 5 (eBioscience), mouse
anti-mouse IgG2bκ CD86 PE-Cyanine 5 (eBioscience), rat anti-mouse
IgG2a CD4 FITC (eBioscience), rat anti-mouse IgG2bκ MHC II FITC
(eBioscience), rat anti-mouse IgG1λCD25PE, rat anti-mouse IgG2κFoxP3
PE-Cyanine 5 (eBioscience). Tregwere detected by theMouse Regulatory
T cell Staining Kit, according to the manufacturer's instructions
(eBioscience). Prior to intracellular cytokine staining, cells were stimulated
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FIGURE 1 Effects of CI on T1D clinical and histological parameters in different rodent species. (a) Blood glucose of male C57BL/6 mice
injected i.p. for 5 consecutive days with MLDS (40mg/kg/day) (♦) and treated with single i.p. injection of CI (25mg/kg) concomitantly with the
first STZ (□). (b) Body weight of C57BL/6 after T1D induction. (c) Blood glucose of male CBA/H mice injected i.p. for 5 consecutive days with
MLDS (40mg/kg/day) (♦) and treated with single i.p. injection of CI (25mg/kg) given either 7 days before (Δ), concomitantly with the first STZ
(□), or 5 days after the first STZ (×). (d) Body weight of CBA/H mice after T1D induction. (e) Blood glucose of male DA rats injected i.p. for 5
consecutive days with MLDS (20mg/kg/day) (♦) and treated with single i.p. injection of CI (25mg/kg) 7 days before (Δ), or concomitantly with
first STZ (□). (f) Body weight of DA rats after T1D induction. (g) Representative examples of the light microscopic evaluation of the pancreatic
islets. (h) Quantitative histology score of pancreatic islets immune cell infiltrations at day 42 after disease induction. Grade 0 (white bars)
represents islets with well-preserved morphology and without mononuclear cell infiltrates; Grade 1 (grey bars) represents moderate mononuclear
cell infiltrates. Grade 2 (black bars) represents islets with abundant mononuclear cell infiltrates, necrosis, atrophy, and loss of islet margins. (i)
Serum insulin level was measured at day 42 after T1D induction. Results from one representative out of three experiments are presented as
mean ± SD (n = 710 animals per treatment). *p < 0.05 refers to corresponding MLDS animals
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with phorbol myristate acetate (PMA, 100 ng/ml) and ionomycin (400 ng/
ml) (both from SigmaAldrich) in the presence of Brefeldin A (eBioscience)
(5μM) for 4 hr, stainedwith anti-CD4 antibody, fixed in 2% paraformalde-
hyde, permeabilized with Permeabilization buffer (eBioscience) and then
stained for the intracellular cytokines with the following antibodies: rat
anti-mouse IgG1κ IFN-γ PE, IgG1 κ IL-4 PE, IgG1κ IL-17 PE (BD
Biosciences). Cells were also stained for transcriptional factors with the
following antibodies: mouse anti-mouse IgG1κ Tbet PE, rabbit anti-mouse
IgG p-ERK, ERK, p-IκB-α, IκB-α, p-p38 (Cell Signaling Technology, Boston,
MA), followedby incubationwithbiotin-linkedgoatanti-rabbit IgG (Sigma
Aldrich), and subsequent incubation with FITC-streptavidin (BioLegend,
SanDiego,CA). Isotype-matchedcontrolswere included in all experiments
(eBioscience). Stained cells were detected on Partec CyFlow Space and
analyzed by FlowMax software (Partec, Görlitz, Germany). Analysis was
performed only on live cells that were gated on FSC versus SSC plot. All
other gating strategies are explained in Figure legends.
2.11 | Statistical analysis
Data are presented asmeans ± SD. Statistical analysis was performed using
Statistica 6.0 (StatSoft Inc., Tulsa, OK) software. Statistical comparisons
weremadebyone-wayANOVAfollowedbyStudentNewmanKeuls test
formultiple comparisonsor by Student's t-test (two tailed), as appropriate.p
value less than 0.05 was considered to be statistically significant.
3 | RESULTS
3.1 | CI reduces clinical parameters of MLDS-induced
diabetes
To investigate the effect of adjuvant CI on the development of murine T
lymphocyte-dependent diabetes, C57BL/6 mice susceptible to diabetes
inductionwere inoculatedwith CI given as a single intraperitoneal injection
atastartofdiabetes inductionwithMLDS.Strikingly,whereasbloodglucose
level in controlMLDS-inducedmice gradually increased, inmice inoculated
with CI after the initial rise, glucose level rapidly decreased resulting in the
restoration of euglycaemia (Figure. 1a). The suppressive effect of the CI
treatment has been maintained for at least an additional month (data not
shown) and seemingly, CI treatment was well tolerated judging by animal
behavior,bodyweightgain (Figure1b),normal food,andwaterconsumption
and general appearance. Since the disease may differ in some aspects in
individual inbredstrains,CBA/Hmice,whichhave lowerbasalbloodglucose
level in comparison to C57BL/6 mice, were examined as well. In order to
avoid interference with STZ, CI was injected either 7 days before the first
(pre-treatment), or 1 day after the last STZ injection (post-treatment).
FIGURE 2 Effects of CI on the cellular changes in the spleen induced by MLDS in C57BL/6 mice. (a) Ex vivo cytokine secretion from SC
isolated from MLDS and CI +MLDS mice determined by ELISA. (b) Percentage of pro-inflammatory F4/80+CD40+ and anti-inflammatory
F4/80+CD206+ macrophages within spleen in MLDS and CI +MLDS treated animals measured by flow cytometry. Only live cells were gated
and subjected to analysis. (c) Distribution of T cells within spleen of mice treated with MLDS or CI +MLDS measured by flow cytometry. Live
cells were gated. Treg cells were defined as FoxP3+ cells within CD4+CD25high cells. Representative dot plots are displayed along with graphs.
Results from one representative out of three experiments are presented as mean ± SD (n = 710 animals per treatment). *p < 0.05 refers to
corresponding MLDS animals
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Inoculation of CI (irrespective of delivery time) to CBA/H mice provided a
measurable level of protection (Figure 1c) similar to that obtained in
C57BL/6mice. Also, CI treatment did not interfere with the weight gain of
the animals (Figure 1d). Because rats are more sensitive than mice cells to
diabetogenic dosesof streptozotocin (Stosic-Grujicic et al., 2001), theeffect
of CI in DA rats was further investigated. As in the mouse, a significant
suppressiveeffecthadbeenobservedandwassimilarwhetherCI treatment
started before, or simultaneously with MLDS application (Figure 1e). In
addition, body weight gain was not affected by CI treatment (Figure 1f).
Thus, in both rat andmousemodels ofMLDS T1D, the protective effect of
single dose of CI was substantial and long-lasting with limited variations of
blood glucose levels throughout the entire 42-days follow-up period.
To prove that CI interfered with autoimmune process during T1D
development andnotwith glycemiaper se, CIwas administered toC57BL/
6mice that received toxicdoseofSTZ (200mg/kgbw). Indeed,mice inboth
control group (treated with STZ+PBS) and in STZ+CI-treated group
developed hyperglycemia 72hr after STZ injection (21.9 ±3.4 vs.
21.1 ± 10.2mmol/L, respectively, p=0.876), indicating that CI was unable
to alter glycemia in animals with completely destroyed pancreatic islets.
3.2 | CI treatment prevents insulitis and preserves
insulin production in MLDS-treated C57BL/6 mice
Consistent with the clinical findings, pathohistological analysis of the
pancreata of CI-treated and vehicle-treated diabetic mice revealed
substantial differences. In contrast to islets of vehicle-treated diabetic
mice that exhibited varying degrees of mononuclear cell infiltration
(insulitis) and progressively lost clear margins due to beta cell
destruction, the majority of pancreatic islets from CI-treated animals
appeared normal, with little or no signs of inflammation or destruction
(Figure 1g). Quantitative analysis of mononuclear cell infiltration of
pancreas performed at the end of the study (42 days post-MLDS)
revealed that CI-treated mice had significantly increased grade 0
(normal) and significantly decreased grade 2 islets (with insulitis)
compared with control diabetic mice (Figure 1h). Notably, CI appeared
to preserve not only the number, but also the function of pancreatic
beta cells, judging by the higher systemic insulin concentrations in the
sera of CI-treated comparedwith vehicle-treatedMLDSmice at day 42
after T1D induction (Figure 1i). Overall, these data indicated that CI
treatment preserved islets from autoimmune attack, thus enabling
appropriate regulation of plasma glucose level.
3.3 | The effect of CI treatment on the immune
response in the spleen
To elucidate the mechanisms by which systemic CI treatment prevents
disease onset when given simultaneously with the disease induction, ex
vivo studieswere performedonperipheral lymphoidorgans ofC57BL/6
mice during early progression of the MLDS-induced diabetes (15 days
after diabetes induction). Spleens were collected from CI-treated or
vehicle-treated group ofmice, and cytokine releasewas assayed ex vivo
without further stimulation. The data summarized in Figure 2a clearly
show that SC isolated fromCI-treatedmice released increased amounts
of anti-inflammatory cytokines IL-4 and IL-10, compared with control
diabetic animals. Interestingly, while secretion of pro-inflammatory
IFN-γ was not changed after CI treatment, IL-17 secretion was up-
regulated (Figure 2a). Phenotype analysis of splenocytes (Figure 2b)
showed that CI significantly reduced the percentage of F4/80+CD40+
(pro-inflammatory M1) macrophages, while the proportion of the
alternatively activated CD206+ (M2 polarized) macrophages was not
significantly changed. Although the proportion of M1 was down-
regulated, their production of pro-inflammatory cytokines remained the
same as in MLDS-derived splenic macrophages (MLDS vs. MLDS + CI:
IL-1β91 ± 23 pg/ml vs. 99 ± 18 pg/ml, TNF2309 ± 76 pg/ml vs.
2200 ± 110 pg/ml, and IL-61904 ± 148 pg/ml vs. 1951 ± 92 pg/ml).
Also, while CI did not affect the relative sizes of both CD4+and
CD8+T cell populations, as well as the proportion of cells with Treg
markers (FoxP3+ cellswithinCD4+CD25high cell population), it produced
a significant decrease in the number of activated CD4+CD25low T cells
(Figure 2c).
3.4 | CI treatment induces in vitro NO-mediated
suppressor function of peritoneal cells
Since our results indicated that CI lowers the number of pro-
inflammatory macrophages in the spleen, we further investigated
FIGURE 3 Effects of CI treatment on PC function of diabetic
C57BL/6 mice. (a) Intracellular NO production in PC of MLDS-treated or
CI +MLDS-treated C57BL/6 mice measured by flow cytometry.
Representative dot plot is shown on the right hand side. (b) 1 ×104 PC
cells from MLDS or CI +MLDS-treated C57BL/6 mice were co-cultured
with 5×105 untreated LNC in the presence of 1µg/ml ConA. Cell
proliferative response was measured by [3H] thymidine incorporation
after 72 hr (left) and NO release into 48 hr co-culture supernatants was
measured by Griess reaction (right). Results from one representative out
of three experiments are presented as mean±SD (n=710 animals per
treatment). *p<0.05 refers to corresponding MLDS-treated animals
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the effect of CI on the peripheral immune cells in other compart-
ments. Results showed that macrophages from peritoneal cavity of
CI-treated MLDS-induced mice contained significantly more
intracellular NO in comparison with cells from control animals
(Figure 3a). To examine whether CI-induced up-regulation of
peripheral NO production influences T cell activation, we
performed a suppression assay of the conventional T cell response
to a mitogen. To do this, PC isolated from CI-treated or control
FIGURE 4 CI treatment of MLDS-induced C57BL/6 mice alters immune cell composition of PLN and PP. (ac) Distribution of T cells within
PLN of MLDS and CI +MLDS treated C57BL/6 mice measured by flow cytometry. (d) Percentage of IFN-γ+ and IL-17+ PP cells isolated from
MLDS and CI +MLDS-treated C57BL/6 mice measured by flow cytometry. Live cells were gated. Representative dot plots are displayed along
with the graphs. Results from one representative out of three experiments are presented as mean ± SD (n = 710 animals per treatment).
*p < 0.05 refers to corresponding MLDS-treated animals
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MLDS-induced mice were co-cultured with ConA-stimulated
lymphocytes derived from control C57BL/6 mice. As shown in
Figure 3b, LNC proliferative response to mitogen was lower in the
presence of CI-treated PC when compared to vehicle-treated PC.
In contrast, CI-derived PC released higher concentrations of NO
than cells isolated from vehicle-treated mice suggesting that
lowered T cell proliferation was a consequence of the active
suppression by CI-induced macrophage-derived NO.
FIGURE 5 CI treatment suppresses pro-inflammatory response in pancreatic mononuclear infiltrates of MLDS-induced C57BL/6 mice. (a)
Number of M1 and M2 macrophages within PMI isolated from MLDS and CI +MLDS-treated mice assessed by flow cytometry. (b and c)
Distribution of T cells within PMI of MLDS and CI +MLDS treated cells measured by flow cytometry. (d) Proportion of IFN-γ+, IL-4+, and
IL-17+ cells within PMI of MLDS and CI +MLDS treated mice measured by flow cytometry. Live cells were gated. Representative dot plots
are displayed along with the graphs. Results from one representative out of three experiments are presented as mean ± SD (n = 710 animals
per treatment). *p < 0.05 refers to corresponding MLDS-treated animals
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3.5 | CI modulates cell phenotype in pancreatic
lymph nodes and Peyer's patches
Since the initial events at the level of lymph nodes draining the target
organ might have the major influence on the disease output, we
analyzed different immune cell subsets in pancreatic lymph nodes. To
determine the mechanism of suppression mediated by CI, we initially
examined the possible role of Treg cells in conferring protection from
T1D. Flow cytometry analysis revealed that CI treatment significantly
increased the number of FoxP3+ cells within CD4+CD25high T
lymphocytes, without changing the proportion of CD4+T cells
(Figure 4a). Next we analyzed another possible subset of cells that
might be involved in protection from T1DNKT cells, which are
heterogeneous subset of T cells that show both properties of T cells
and that of natural killer cells (NK) (Lehuen et al., 1998). The results
indicated that CI treatment significantly elevated number of NKT cells
in PLN compared to control MLDS-treated mice (Figure 4b). We also
analyzed CD4+ cell subsets Th1, Th2, and Th17 cells that produce
signature cytokines IFN-γ, IL-4, and IL-17, respectively. The data from
these experiments suggest that the treatment of mice with CI
antagonized the pro-inflammatory response (IFN-γ), while it had no
effect on anti-inflammatory (IL-4) response, at least in the PLN
(Figure 4c). Interestingly, CI treatment significantly elevated the
number of Th17 cells (Figure 4c). Similar effects of CI were observed in
gut-associated lymphoid tissue, Peyer's patches, where the treatment
of MLDS-treated mice with CI significantly decreased the number of
IFN-γ producing cells whichwas accompaniedwith significant increase
in IL-17-producing cells (Figure 4d). Together, these data indicate
protective role of CI in T1D development through the shift from pro-
inflammatory Th1 towards protective Treg/NKT response.
3.6 | CI treatment inhibits infiltration of immune
cells and suppresses pro-inflammatory response
in the pancreas
As infiltration of multiple immune cells into islets (insulitis) is the major
T1D trait in both mice and humans (Eizirik, Colli, & Ortis, 2009), we
performed flow cytometry analysis of PIMC. Composition of infiltrates
clearly showed that CI treatment prevented islet destruction by
modulating both innate and adaptive immunity towards protective
anti-inflammatory response in the target tissue. Number of M1
macrophages, key drivers of disease activity in the effector phase of
T1D, was significantly decreased in CI treatedmice (Figure 5a). Also, CI
treatment altered the composition of T cells, with significant increase
in the number of protective Tregs and NKT cells within the pancreatic
infiltrates (Figures 5b and 5c). We further analyzed PIMC for the
production of IFN-γ, IL-4, and IL-17 and showed that CI treatment
significantly decreased number of pro-inflammatory IFN-γ-producing
cells with simultaneous elevation in the number of anti-inflammatory
IL-4-producing cells, while it had no significant effect on the number of
IL-17-producing cells (Figure 5d). Therefore, CI treatment successfully
suppressed pro-inflammatory response in target tissue by skewing it
towards protective Treg/Th2/NKT response.
FIGURE 6 The effect of CI on the expression of co-stimulatory molecules on immature and mature dendritic cells. Flow cytometry FSC versus SSC
plots (a) and light microscopy image (b) showing C57BL/6 bone marrow-derived dendritic cells (DC) that engulfed CI after 24hr in vitro incubation.
Proportion of immature DC, mature DC, and immature DC (1×106 cells) stimulated with LPS (100ng/ml) that express CD11c (marker for dendritic cells)
and CD40 (c) MHC class II and CD80 (d) and MHC class II and CD86 (e) in the presence or absence of CI (250μg/ml), measured by flow cytometry. Live
cells were gated. Results from one representative out of three experiments are presented as mean±SD. *p<0.05 refers to untreated DC
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Inaddition to thedown-regulatoryeffectofCIon thenumberof IFN-γ-
producing cells in vivo, in vitro results indicate that CI affected IFN-γ
expression per cell (Supplementary Figure S1A) and that this effect was
probably mediated by the reduction of Tbet (key transcription factor for
IFN-γ) (Supplementary Figure S1B) and NF-κB expression (Supplementary
FigureS1C). Seemingly, p38 (SupplementaryFigureS1D) andERKmitogen-
activated protein kinase (Supplementary Figure S1E) were not involved in
the observed IFN-γ reduction exerted by CI. These results suggest that CI
interferedwith IFN-γ production through reduction of transcription factors
relevant for optimal expression of this cytokine.
3.7 | CI down-regulates expression of co-stimulatory
molecule on dendritic cells in vitro
The obtained results indicate that CI modulated the T cell-mediated
immune response during T1D pathogenesis. However, it is reasonable to
assume that CI acts first on phagocytic cells due to its particulate nature.
To investigate whether CI exerts direct effect on maturation and DC
function, we have treated DC in vitro with 250µg/ml CI at different time
points during thematuration process. As deduced by flow cytometry FSC
vs SSC plots (Figure 6a) or light microscopy (Figure 6b), DC phagocytized
CI after 24 hr of incubation. Results indicate that CI did not affect the
expression of co-stimulatory molecules in immature DC (Figure 6ce).
However, it significantly interfered with the DC maturation process
(LPS-provoked) regarding CD40 and CD80 co-stimulatory molecules
expression (Figures 6c and 6d), while the expression of CD86 remained
the same as before CI treatment (Figure 6e). Mature DC were more
resistant to CI-mediated effect since only CD80 expression was reduced
(Figure 6d). These results indicate that CI might interfere with DC
maturation and subsequent stimulation of T cells.
4 | DISCUSSION
This study shows that the intraperitoneal administration of CI suppresses
T1D development in MLDS-treated C57BL/6 mice. The observed effect
ofCI onT1Dwas neither strain nor species restricted, judging by its ability
to suppresshyperglycemia inbothCBA/Hmice andDArats.CI exerted its
immunomodulatory activity through modulation of macrophage activity
and by boosting the regulatory arm of the immune response.
The propensity of adjuvants to block autoimmunity has been already
shown in many cases (Kies & Alvord, 1958; Lee et al., 2008; Sadelain, Qin,
Lauzon, et al., 1990; Sadelain,Qin, Sumoski, et al., 1990). In this study, a single
injection of CI (administered alone) provided long-lasting protection from
MLDS-triggered T1D in animals. Similar results were obtained with single
CFA injection given to NOD mice (Lee et al., 2008, Tian et al., 2009).
Compared to these studies that hypothesize the inhibitory effect of the
adjuvant onautoreactive cytotoxic T cells,NK, andNKT,weassumed thatCI
acts first onphagocytic cells. Indeed, our study showedprofoundeffect ofCI
onmacrophagepolarizationandsuppressor function, in termsof loweringthe
proportion of pro-inflammatory M1 macrophages in spleen and pancreatic
infiltrates, and by enhancing their capacity to suppress T cell proliferation in
vitro. The influence of the iron on favoring macrophage anti-inflammatory
phenotype was shown in the other study performed by Corna et al. (2010).
Decrease inM1macrophages after CI treatment probably led to a reduction
inthenumberofactivatedTcells (CD4+CD25low)observed in thespleen.This
effect might be mediated by NO that is produced by the remaining M1
macrophages.NOwasalready shown toexhibit direct cytostatic effectsonT
cells and APC or through depletion of L-arginine during the iNOS reaction
(Bingisser,Tilbrook,Holt,&Kees,1998;Bogdan,2011).NOcanpreferentially
down-regulate Th1-type cytokines resulting in a Th2 bias (Taylor-Robinson,
1997). Also, the CI-mediated interference with IL-12 production by
phagocytes could also lead to less Th1 reactivity in the presence of NO
(Mattner et al., 1993). Our in vitro experiments confirm that NO might
interfere with T cell-mediated response since macrophages from CI-treated
animals reduced ConA-stimulated T cell proliferation and thus diminished
clonal size of autoreactive T cells. In addition to macrophages, dendritic cells
might also be the primary target for CI. In vitro experiments confirmed that
dendritic cells engulfed CI and consequently reduced the expression of co-
stimulatorymolecules CD40 andCD80. Therefore, the potential of dendritic
cells to activate autoreactiveTcellswas significantlydown-regulated (at least
observed in vitro) or they had become tolerogenic under persistent signaling
provided by the presence of CI (Liu & Cao, 2015).
Different T cell subsets have different roles in T1D pathogenesis.
Th1 and Th17 lymphocytes are thought to be generally involved in the
promotion of the disease, while Th2 and Treg cells suppress T1D
development (Bluestone, Herold, & Eisenbarth, 2010). Inhibition of
Th1 signature cytokine IFN-γ by CI found in regional lymphoid tissues
PLN and PP, as well as in the pancreas seems to be a valid explanation
for the beneficial effect of the CI in T1D. This is in line with the animal
studies that used specific IFN-γ inhibitors for the therapy of
autoimmune diabetes induced in DP-BB rat or C57BL/6 mice or
NOD mice (Cockfield, Ramassar, Urmson, & Halloran, 1989; Nicoletti
et al., 1996, 1997). Interesting finding in this study was that mice
treated with CI had elevated number of Th17 cells in both PLN and PP.
This could also be a positive outcome of CI treatment since it was
shown that in some settings Th17 protected animals against T1D
(Candon et al., 2015; Kriegel et al., 2011). Furthermore, IL-17 silencing
did not prevent T1D development in NOD mice (Joseph, Bittner,
Kaiser, Wiendl, & Kissler, 2012) again suggesting that Th17 cells might
not be involved in T1D pathogenesis or even might exert protective
role. In support to this, it was reported that the rise in the level of IL-17
after adjuvant therapy in NOD mice has a protective effect on T1D
(Nikoopour et al., 2010). However, the role for IL-17 in T1D is still
controversial as other data suggest that therapeutic effects of adjuvant
treatment may be partially due to suppressing Th17 commitment (Gao
et al., 2010), and that blockade of IL-17 may prevent autoimmune
diabetogenesis (Kuriya et al., 2013). The regulatory role of Th17 is
especially true within the intestine where these cells participate in the
maintenance of intestinal homeostasis rather than inducing inflamma-
tion (Zhao et al., 2017). It has been shown recently that both
pathogenic Th17 cells and non-pathogenic regulatory Treg17 cells can
be generated from CD4+ T cells under appropriate polarization
conditions (Bellemore et al., 2015; Volchenkov, Nygaard, Sener, &
Steen Skålhegg, 2017). These studies support our findings that not all
Th17 cells are pathogenic or their up-regulation in the gut immune
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system is merely a reaction to a change in microbiota composition that
occurs during T1D development (Costa et al., 2016).
Inducible Tregs develop fromCD4+T cells in the lymphoid tissues in
response to specific antigens in the presence of TGFβ and IL-10 and in
the absenceof pro-inflammatory cytokines such as IFN-γ, IL-1, IL-6, and
IL-12 (Vignali, Collison, & Workman, 2008). Present study showed that
CI treatment provoked the increment of CD4+Foxp3+ T cells frequency
andsecretionof their signature cytokine IL-10.Again, thepossibility that
CI stimulatedDC tolerogenic phenotypemight beoneof the reasons for
increased regulatory T cell development. These data suggest that CI
prevents the onset of hyperglycemia inmice through the suppression of
effector T cells function by the regulatory arm of the immunity.
Deficiency in NKT contributes to the pathogenesis of autoimmune
diabetes in NODmice as they are able to suppress the development of
autoreactive T cells (Yang, Bao, & Yoon, 2001). NKT produce various
cytokines, such as IL-4, IFN-γ, IL-17, and IL-10 (Novak& Lehuen, 2011).
Our study showed that CI treatment elevated number of NKT cells in
PLN and PIMC. It is therefore intriguing to speculate that treatment by
CI favors protective cytokine secretion profiles (Th2 inclined) in NKT
cells. Also, observed elevated IL-17 production could stem from iNKT
cells (Cua & Tato, 2010) and therefore could be utilized to suppress the
adaptive immunity. This is not in accordance with adjuvant effect of CI
observed in EAE model were the CI treatment induced EAE by
expandingNK andNKT cell population (Miljkovic et al., 2011). Different
CI effects in vivo could reflect differences between disease models or
differences in the CI delivery route.
In conclusion,wehaveprovidedevidence thatCI is effective inhibitor
ofT1Ddevelopment.This inhibitoryeffectmightbedue, at least inpart, to
thesuppressionof innate immunecomponents thatcould lead to impaired
activation and proliferation of T lymphocytes (especially Th1). On the
other side, there is a substantial increase in the regulatory arm of the
immune system after CI treatment. This notion may have therapeutic
implications not only for T1D, but also for other autoimmune diseases
with Treg defects, suggesting that CImay serve as a useful therapeutic for
reducing inflammation and ameliorating autoimmunity.
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